StemSight develops off-the-shelf cell therapies to address unmet medical needs in corneal blindness, combining iPS-derived cells with functional biomaterials to accelerate tissue regeneration and enhance the safety of cell therapies.

StemSight

StemSight - Vision Unlimited | 1,184 followers on LinkedIn. Curing blindness with regenerative cell therapies. | StemSight develops off-the-shelf regenerative cell therapies for corneal blindness. Our expertise is in the combination of iPS-derived cells with functional biomaterials - for FASTER tissue regeneration, SAFER cell therapies and EASIER cell delivery.

Cell therapy executive, entrepreneur, investor...

Lee Buckler

Laboratory Assistant at StemSight Oy - Biomedical engineer, Tissue engineering enthusiast and Stem cell scientist

Liisa Ikonen

Board professional, biotech startups and foundations, with a private passion for landscaping and historical gardens

Anna Ehrnrooth

CSO, StemSight, Tampere, Finland; Adjunct Professor, senior researcher at Tampere University

Tanja Ilmarinen

StemSight - Vision Unlimited

ICYMI: Ground-breaking work from Professor Kohji Nishida's team at Osaka University in using iPS cell-derived cell sheets to treat Limbal stem cell deficiency published this week! 👁 Results from their first-in-human clinical trial showed no serious adverse events in the 4 patients treated, and improvement in vision in 3 of the treated patients after one year. 👁 We are very excited to see this progress and validation for the safety of iPS cell-based therapies in treatment of severe eye diseases, like LSCD. These therapies truly have the capability to change patients lives in the future!

🌟 What an inspiring 3 days at BIO-Europe in Stockholm! 🌟 Nia Health had the privilege of joining the Startup Spotlight sponsored by Bayer Co.Lab , where we stood alongside an incredible lineup of innovative Biotech startups from across the industry. It was an honor to be chosen as one of just 8 companies presenting our technology to this great community. A special congratulations to this year’s winners, Kadence Bio and Sarcomatrix — your solutions are pushing boundaries in ways that inspire us all! The conference was a deep dive into the transformative potential of digital health, as well as the evolving landscape of drug discovery and development. It’s clear that integrating digital therapeutics with traditional pharmaceutical approaches is redefining how we address complex health needs and bring innovative solutions to patients. BIO-Europe also offered a wealth of opportunities to connect with industry leaders, investors, and like-minded innovators. Through these conversations, we gained valuable insights into the challenges and advancements in drug discovery, underscoring the importance of cross-sector collaboration to deliver impactful therapies efficiently and effectively. Thank you EBD Group for hosting, and everyone who made these days both memorable and meaningful. We look forward to what’s next and to continuing this journey of innovation together! #BIOEurope #Healthcare #DigitalHealththeratrame Harmonic Discovery Loma Therapeutics StemSight - Vision Unlimited THERAtRAME V4CURE

Nia Health GmbH

Blindness is unique to everyone. We asked individuals with vision loss to describe what they see in the same painting, and each response was different. Why? Because blindness is a spectrum! Join our #ShareYourVision campaign this October and share your unique perspective. Let’s come together to inspire and educate others about the diverse experiences of vision loss. https://lnkd.in/e29Pk26z Video Description: Individuals each sit in front of a scenic image of a red hot air balloon floating over a grassy area with a red house, a small river, ducks, and horses, with two large mountains in the background, and describe what they can see.

Foundation Fighting Blindness

We all have stories to share, and we want to see yours! With the International Agency for the Prevention of Blindness (IAPB), we are proud to present the World Sight Day 2024 Photo Competition! Submit your images today at https://lnkd.in/g35p9wNP Bayer is a proud supporter of the IAPB World Sight Day Photo Competition. #WorldSightDay ❤️ #LoveYourEyes

Bayer | Ophthalmology

👁️👓 Eye health innovation is vital as our aging population and increased screen use put more strain on vision. Ongoing research is essential to develop solutions that preserve and enhance sight, addressing challenges like early detection, treatment, and accessibility. The online scientific partnering platform Inpart has published a new report exploring eye health R&D trends and breakthrough innovations, which we are pleased to have Tampere University technology and spin-off StemSight - Vision Unlimited featured in! ✨ Discover how our StemSight - Vision Unlimited is impacting vision care globally. Download the report here: https://lnkd.in/gZwiUhia #eyehealth #eyehealthinnovation #visioncare #techtransfer #ophthalmology #medicalinnovation #visionscience #openinnovation

Juho Väisänen

🤝 Meet the BIO-Europe® 2024 Startup Spotlight finalists! With over 60 submissions from the most dynamic biotech startups, selecting just 8 finalists was quite a challenge. This is your opportunity to hear directly from the finalists as they showcase their innovations and discuss the visions that hold the potential to reshape the future of healthcare! Don't miss out on this thrilling competition, register for Bio-Europe today and save €600 on your pass >> https://lnkd.in/gSmS3EBb Thank you to Bayer Co.Lab for sponsoring the Startup Spotlight. #BIOEurope #biotech #StartupSpotlight #Innovation #Entrepreneur

EBD Group

StemSight is in the finals of this year's BIO Europe Startup Spotlight! Our CEO Laura Koivusalo will be taking the stage in Stockholm with 7 other early-stage biotech and healthtech startups on Nov 4-6. See all the finalists here 👉 https://lnkd.in/gf7zueFY #Stemsight #VisionUnlimited #CuringBlindess #BIOEurope2024 #StartupSpotlight #PitchingCompetition

15 years ago, the first Advanced Therapy Medicinal Product ( #ATMP ) regulation in the EU was passed, and the Committee of Advanced Therapies formed as a result. In that time, 27 novel treatments for unmet medical needs have been approved. What will the next 15 years of ATMPs look like?

Tommorow, June 11th, our CEO Laura Koivusalo will be in London presenting at the #BioSeed Summer edition. We are excited to talk to early-stage biotech investors about StemSight's open Seed investment round!

Have you read our latest interview in European Biopharmaceutical Review (EBR) ? Following the addition of StemSight - Vision Unlimited to our family of licensees earlier this year, our CEO, John E. Milad , and StemSight’s CCO, Ross Macdonald , discuss how #CRISPRCas9 has become a transformative tool in life sciences and their predictions for the next five years, including the need for licensing as a means to foster collaboration and knowledge exchange. Read the article here: https://shorturl.at/0dgFD

ERS Genomics

Microsoft Exchange Online

Office 365 Mail

Co-Founder and CTO

Heli Skottman

Aapo Kiviniemi

Chief Legal Officer

Anni Mörö

Chief Scientific Officer

Laura Koivusalo

founder and CEO

Co-Founder

European Union (EU) Companies With Less Than $500M in Revenue (Top 10K)

European Union (EU) Seed Stage Companies With Fewer Than 10 Employees (Top 10K)

Biotechnology Companies (Top 10K)

Nordic Countries Companies With Fewer Than 1000 Employees (Top 10K)

StemSight is a cell therapy startup developing novel treatments for blindness operating in Tampere, Finland.

Avohoidon Tutkimussäätiö

Voima Ventures

Seed Round - StemSight

Tampere

Western Finland

Finland

Europe

StemSight and ERS Genomics focus on collaboration - PharmaTimes

ERS Genomics and StemSight Sign CRISPR/Cas9 License Agreement

StemSight and ERS Genomics focus on collaboration

ERS Genomics and StemSight Sign CRISPR/Cas9 License Agreement - BusinessWire

A cell therapy product designed to treat limbal stem cell deficiency (LSCD), aiming to restore vision for patients with this condition.

Development of stem cell-based treatments for corneal endothelial dystrophies to address corneal cell loss and swelling.

Incorporation of CRISPR/Cas9 technology for gene editing in the development of cell therapy products.

Joint research projects with Tampere University focusing on regenerative solutions for treating blindness.

news impact assignment basic	general
public peers	general	Nov 19, 2024 5:54 AM	01a9457a
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 19, 2024 5:54 AM	78cffd81
crunchbase trigger	general	Nov 19, 2024 5:54 AM	0d18b49f
crunchbase profile	general	Nov 19, 2024 11:45 PM	ba7071a0
li profile	general	Nov 19, 2024 5:54 AM	07aba82d
translate crunchbase fundingrounds	general	Nov 20, 2024 12:30 AM	be1a94de
peers	general	Nov 19, 2024 5:54 AM	98921573
news basic	general	Nov 19, 2024 5:54 AM	cf918627
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

STEM

FI:STEMSIGHT

StemSight